Plexxikon, Roche to work together on new class of cancer drugs

10/9/2006 | American City Business Journals

Roche will pay up to $700 million to Calif.-based biotech Plexxikon to create a new early-stage cancer therapy based on the biotech's compound, which attracted a lot of attention. The drug selectively inhibits a genetic mutation, called B-RafV600E kinase, found in more than 70% of malignant melanomas and a large percentage of other cancers and tumor types.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI